Unity Biotechnology is a biotechnology company engaged in the research and development of therapeutics to slow, halt, or reverse diseases of aging. Co. focuses on creating senolytic medicines to selectively eliminate senescent cells and thereby treat diseases of aging, such as ophthalmologic diseases. Co.'s ophthalmology program includes UBX1325, which is its main drug candidate for age-related diseases of the eye including diabetic macular edema, age-related macular degeneration and diabetic retinopathy. Co.'s neurology program includes UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain. The UBX stock yearly return is shown above.
The yearly return on the UBX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the UBX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|